8th Microbiome Movement Drug Development Summit
By
Hanson Wade
2 Followers
Follow
Event Details
8th Microbiome Movement Drug Development Summit
The 8th Microbiome Movement Drug Development Summit returns in 2023 as North America's definitive microbiome drug development event - and it's back bigger and better than ever!
The microbiome-based therapeutic market is rapidly evolving, and it's more important than ever to showcase the efficacy of microbial-based approaches beyond C. difficile. Discover how drug developers are advancing their understanding of the role of the microbiome in disease and harnessing functionally relevant microbes for live biotherapeutic approaches.
Join us, as we provide in-depth insights into the interactions between the microbiome and metabolic pathways, host-microbe relationships in novel preclinical models, and the application of microbial-based biomarkers in clinical endpoints and diagnostic settings. Our sessions also cover the mechanistic rationale behind combination therapies, new smart clinical trial data, and GMP compliant manufacturing for stable products.
With more speakers, content, and networking than ever before, this is set to be the best version of the event yet and you cannot afford to miss it!
URLs:
Brochure: https://go.evvnt.com/1616021-0?pid=10018
Website: https://go.evvnt.com/1616021-1?pid=10018
Tickets: https://go.evvnt.com/1616021-2?pid=10018
LinkedIn: https://go.evvnt.com/1616021-4?pid=10018
Prices:
Pharma and Biotech Pricing: Conference Only (save $700): USD 2299.00,
Solution and Service Provider Pricing: Conference Only (save 500): USD 3099.00,
Academic, Not-For-Profit Provider and Start-Up Pricing: Conference Only (save $700): USD 1699.00
Speakers: Aaron Cowley, Chief Scientific Officer, Arranta Bio, Alicia Szretter, Associate Director, Vedanta Biosciences Inc, Brett Noel, Innovation Lead, Sanofi, Kyle Jacoby, Vice President - Biology, Federation Bio, Michelle Rooks, Associate Fellow - Research, Pfizer, Paul Carlson, Principal Investigator, FDA, Rebecca Senter, Vice President, Head of Preclinical Research and Development, Axial Therapeutics, Inc., Robert Brucker, Co-founder and Chief Scientific Officer, DermBiont, Samantha Coulson, Head of Clinical Research, Servatus ltd., Yvonne Nyavor, Principal Scientist, Boston Analytical, Trevor Lawley, Chief Scientific Officer and Founder, Microbiotica, Travis Whitfill, Chief Operating Officer, Azitra Inc., Tariq Warsi, Vice President Technical Operations, Novome Biotechnologies , and many more
The microbiome-based therapeutic market is rapidly evolving, and it's more important than ever to showcase the efficacy of microbial-based approaches beyond C. difficile. Discover how drug developers are advancing their understanding of the role of the microbiome in disease and harnessing functionally relevant microbes for live biotherapeutic approaches.
Join us, as we provide in-depth insights into the interactions between the microbiome and metabolic pathways, host-microbe relationships in novel preclinical models, and the application of microbial-based biomarkers in clinical endpoints and diagnostic settings. Our sessions also cover the mechanistic rationale behind combination therapies, new smart clinical trial data, and GMP compliant manufacturing for stable products.
With more speakers, content, and networking than ever before, this is set to be the best version of the event yet and you cannot afford to miss it!
URLs:
Brochure: https://go.evvnt.com/1616021-0?pid=10018
Website: https://go.evvnt.com/1616021-1?pid=10018
Tickets: https://go.evvnt.com/1616021-2?pid=10018
LinkedIn: https://go.evvnt.com/1616021-4?pid=10018
Prices:
Pharma and Biotech Pricing: Conference Only (save $700): USD 2299.00,
Solution and Service Provider Pricing: Conference Only (save 500): USD 3099.00,
Academic, Not-For-Profit Provider and Start-Up Pricing: Conference Only (save $700): USD 1699.00
Speakers: Aaron Cowley, Chief Scientific Officer, Arranta Bio, Alicia Szretter, Associate Director, Vedanta Biosciences Inc, Brett Noel, Innovation Lead, Sanofi, Kyle Jacoby, Vice President - Biology, Federation Bio, Michelle Rooks, Associate Fellow - Research, Pfizer, Paul Carlson, Principal Investigator, FDA, Rebecca Senter, Vice President, Head of Preclinical Research and Development, Axial Therapeutics, Inc., Robert Brucker, Co-founder and Chief Scientific Officer, DermBiont, Samantha Coulson, Head of Clinical Research, Servatus ltd., Yvonne Nyavor, Principal Scientist, Boston Analytical, Trevor Lawley, Chief Scientific Officer and Founder, Microbiotica, Travis Whitfill, Chief Operating Officer, Azitra Inc., Tariq Warsi, Vice President Technical Operations, Novome Biotechnologies , and many more
Entry Fees
Free Registration
Categories
Event Frequency
One Time
Event Timings
(GMT-4:00) Eastern Time (US and Canada)
08:30 AM - 05:40 PM (Jun 28, Jun 29, Jun 30) (Public)
Speakers
Gallery Images
Organizer
Hanson Wade
2 Followers
Follow
Hanson Wade specialises in bringing people together through outstanding business conferences and year round community contact.
More Events By Hanson Wade
Comments on 8th Microbiome Movement Drug Development Summit
You must Login to write a comment.
Peoples Interested in Visit
0 Peoples Interested to Visit
Event Location
Omni Boston Hotel at the Seaport
450 Summer Street ,
Boston 02210, Massachusetts, United States
Boston 02210, Massachusetts, United States
Official Link :
Social Media